IMC Chicago
REGN icon

IMC Chicago’s Regeneron Pharmaceuticals REGN Stock Holding History

IMC Chicago’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.2M Sell
98,600
-22,300
-18% -$17.1M 0.03% 364
2025
Q4 		$93.3M Buy
120,900
+900
+0.8% +$611K 0.03% 304
2025
Q3 		$67.5M Buy
120,000
+8,300
+7% +$4.69M 0.02% 374
2025
Q2 		$58.6M Buy
111,700
+41,500
+59% +$23.2M 0.03% 343
2025
Q1 		$44.5M Buy
70,200
+28,500
+68% +$19.6M 0.03% 349
2024
Q4 		$29.7M Buy
41,700
+31,700
+317% +$26.6M 0.01% 473
2024
Q3 		$10.5M Sell
10,000
-1,500
-13% -$1.67M 0.01% 797
2024
Q2 		$12.1M Sell
11,500
-2,600
-18% -$2.52M 0.01% 713
2024
Q1 		$13.6M Sell
14,100
-10,300
-42% -$9.79M 0.01% 593
2023
Q4 		$21.4M Buy
24,400
+7,900
+48% +$6.51M 0.01% 438
2023
Q3 		$13.6M Sell
16,500
-33,200
-67% -$26.1M 0.01% 471
2023
Q2 		$35.7M Buy
49,700
+12,100
+32% +$9.33M 0.03% 254
2023
Q1 		$30.9M Buy
37,600
+15,400
+69% +$11.6M 0.04% 249
2022
Q4 		$16M Sell
22,200
-4,000
-15% -$2.95M 0.03% 357
2022
Q3 		$18M Buy
+26,200
New +$16.5M 0.02% 311
2022
Q1 		– Sell
-23,700
Closed -$15M – 1208
2021
Q4 		$15M Sell
23,700
-18,000
-43% -$11.1M 0.01% 415
2021
Q3 		$25.2M Buy
41,700
+16,300
+64% +$10.1M 0.03% 311
2021
Q2 		$14.2M Sell
25,400
-19,500
-43% -$9.88M 0.02% 392
2021
Q1 		$21.2M Sell
44,900
-28,200
-39% -$13.7M 0.03% 277
2020
Q4 		$35.3M Buy
73,100
+38,000
+108% +$20.5M 0.05% 173
2020
Q3 		$19.6M Sell
35,100
-4,300
-11% -$2.61M 0.03% 210
2020
Q2 		$24.6M Sell
39,400
-11,900
-23% -$6.75M 0.05% 130
2020
Q1 		$25M Sell
51,300
-500
-1% -$206K 0.05% 115
2019
Q4 		$19.4M Buy
51,800
+38,700
+295% +$13M 0.05% 132
2019
Q3 		$3.63M Sell
13,100
-13,200
-50% -$3.91M 0.01% 348
2019
Q2 		$8.23M Buy
26,300
+7,300
+38% +$2.43M 0.03% 200
2019
Q1 		$7.8M Sell
19,000
-5,200
-21% -$2.14M 0.03% 175
2018
Q4 		$9.04M Buy
+24,200
New +$8.86M 0.03% 131

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IMC Chicago's REGN Position: Q3 2025 in Review

IMC Chicago sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 17,952 shares — an estimated $10.2M sold.

IMC Chicago first reported a position in REGN in Q2 2025 and held it in 1 quarter. The position peaked at $9.42M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • IMC Chicago reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • IMC Chicago sold 17,952 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $10.2M.
  • IMC Chicago first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • IMC Chicago's Regeneron Pharmaceuticals position peaked at $9.42M in Q2 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.